| GC31294-10mg |
|
139652-01-0 |
|
0 |
C27H33NO4 |
|
|
|
| GC31294-5mg |
|
139652-01-0 |
|
0 |
C27H33NO4 |
|
|
|
| GC31294-1mg |
|
139652-01-0 |
|
0 |
C27H33NO4 |
|
|
|
| GC31293-20mg |
|
168830-01-1 |
Heterocyclyl carbamate derivative 1
|
0 |
C26H29N3O2 |
|
|
|
| GC31293-10mg |
|
168830-01-1 |
Heterocyclyl carbamate derivative 1
|
0 |
C26H29N3O2 |
|
|
|
| GC31293-5mg |
|
168830-01-1 |
Heterocyclyl carbamate derivative 1
|
0 |
C26H29N3O2 |
|
|
|
| GC31293-1mg |
|
168830-01-1 |
Heterocyclyl carbamate derivative 1
|
0 |
C26H29N3O2 |
|
|
|
| GC31292-50mg |
|
845959-50-4 |
Mitoquinone mesylate (Mitoquinone methanesulfonate)
|
0 |
C38H47O7PS |
|
|
|
| GC31292-25mg |
|
845959-50-4 |
Mitoquinone mesylate (Mitoquinone methanesulfonate)
|
0 |
C38H47O7PS |
|
|
|
| GC31292-10mg |
|
845959-50-4 |
Mitoquinone mesylate (Mitoquinone methanesulfonate)
|
0 |
C38H47O7PS |
|
|
|
| GC31292-5mg |
|
845959-50-4 |
Mitoquinone mesylate (Mitoquinone methanesulfonate)
|
0 |
C38H47O7PS |
|
|
|
| GC31290-1g |
|
830-96-6 |
|
0 |
C11H11NO2 |
|
|
|
| GC31289-20mg |
|
137315-05-0 |
Urinary Incontinence-Targeting Compound 1
|
0 |
C9H13FN2O3S |
|
|
|
| GC31289-10mg |
|
137315-05-0 |
Urinary Incontinence-Targeting Compound 1
|
0 |
C9H13FN2O3S |
|
|
|
| GC31289-5mg |
|
137315-05-0 |
Urinary Incontinence-Targeting Compound 1
|
0 |
C9H13FN2O3S |
|
|
|
| GC31289-1mg |
|
137315-05-0 |
Urinary Incontinence-Targeting Compound 1
|
0 |
C9H13FN2O3S |
|
|
|
| GC31288-10mg |
|
374538-23-5 |
Neuromuscular Disorder-Targeting Compound 1
|
0 |
C15H25N3S |
|
|
|
| GC31288-5mg |
|
374538-23-5 |
Neuromuscular Disorder-Targeting Compound 1
|
0 |
C15H25N3S |
|
|
|
| GC31288-1mg |
|
374538-23-5 |
Neuromuscular Disorder-Targeting Compound 1
|
0 |
C15H25N3S |
|
|
|
| GC31287-20mg |
|
152886-85-6 |
|
0 |
C13H17N3O |
|
|
|
